Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 330.41M P/E - EPS this Y 96.30% Ern Qtrly Grth -
Income -74.18M Forward P/E -248.78 EPS next Y 161.90% 50D Avg Chg -14.00%
Sales 166.88M PEG -11.73 EPS past 5Y -43.92% 200D Avg Chg -20.00%
Dividend N/A Price/Book 1.19 EPS next 5Y 10.00% 52W High Chg -31.00%
Recommedations 1.00 Quick Ratio 3.70 Shares Outstanding 14.80M 52W Low Chg 4.00%
Insider Own 3.37% ROA 0.01% Shares Float 10.78M Beta 0.84
Inst Own 91.56% ROE -30.63% Shares Shorted/Prior 673.26K/675.30K Price 22.39
Gross Margin 62.61% Profit Margin -44.45% Avg. Volume 80,095 Target Price 34.50
Oper. Margin 0.38% Earnings Date Oct 31 Volume 88,467 Change -2.78%
About Anika Therapeutics Inc.

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

Anika Therapeutics Inc. News
11/22/24 Anika To Participate in December 2024 Investor Conferences
11/01/24 Anika Therapeutics Third Quarter 2024 Earnings: Misses Expectations
11/01/24 Anika Therapeutics Inc (ANIK) Q3 2024 Earnings Call Highlights: Strategic Shifts Amid Revenue ...
10/31/24 Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics
10/31/24 Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates
10/31/24 Anika: Q3 Earnings Snapshot
10/31/24 Anika Reports Third Quarter 2024 Financial Results
10/31/24 Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical
10/30/24 Investors in Anika Therapeutics (NASDAQ:ANIK) have unfortunately lost 61% over the last five years
10/17/24 Anika Announces Third Quarter 2024 Results Conference Call Date
10/09/24 Anika Therapeutics Inc (ANIK) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ...
10/04/24 Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/10/24 Anika Therapeutics, Inc. (NASDAQ:ANIK) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
08/09/24 Anika Therapeutics, Inc. (ANIK): Are Hedge Funds Bullish on This Caligan Partners-Approved Stock?
08/08/24 Anika Therapeutics (ANIK) Q2 Earnings Lag Estimates
08/08/24 Anika: Q2 Earnings Snapshot
08/08/24 Anika Reports Second Quarter 2024 Financial Results
07/25/24 Anika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024
10:31 AM We're Not Worried About Anika Therapeutics' (NASDAQ:ANIK) Cash Burn
07/11/24 Anika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs
ANIK Chatroom

User Image tradingtwenty Posted - 2 weeks ago

Top 5 oversold stocks that have trended in the past 24 hours: $HMST 12.59🔥 $ANIK 13.27 $QRVO 15.89 $SITC 17.76 $ANAB 21.42 Values range from 0 to 100, where 30 or below is oversold and 70 or above overbought. Link: https://tradingtwenty.com/dashboard/trending/past

User Image YouOnlyLiveTwice Posted - 2 weeks ago

$ANIK Train wreck company… Should be sub $12

User Image RealErnFranklin Posted - 2 weeks ago

$anik yes! $RYDE thats how its done $HMST hot hot $NRT the best Holding isnt fun, but look at how small caps reward. 🤟 $SRM 1.6 float, eyes, launch setup. Its a trade, traders.

User Image anachartanalyst Posted - 3 weeks ago

$ANIK https://anachart.com/wp-content/uploads/ana_temp/1730476966_soc-img.jpg

User Image PenkeTrading Posted - 3 weeks ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Anika Therapeutics Inc. Is that bullish or bearish? $ANIK #Anika #RsiOversold #NASDAQ

User Image Doozio Posted - 10/31/24

YO Jon $anik ……. 🐑👀

User Image YouOnlyLiveTwice Posted - 10/31/24

$ANIK Lmao ….should be below $10

User Image mejojo28 Posted - 10/31/24

$ANIK $ANIK, COME JOIN US@ $CVNA. WE RUNNING UP

User Image Estimize Posted - 10/28/24

Wall St is expecting 0.09 EPS for $ANIK Q3 [Reporting 10/31 BMO] http://www.estimize.com/intro/anik?chart=historical&metric_name=eps&utm_co

User Image StockInvest_us Posted - 08/28/24

Signal alert: $ANIK - Possible Runner https://stockinvest.us/l/kokTr9RZNs

User Image StockInvest_us Posted - 08/26/24

Signal alert: $ANIK - Possible Runner https://stockinvest.us/l/0iq89GqtG8

User Image StockInvest_us Posted - 2 months ago

Signal alert: $ANIK - Possible Runner https://stockinvest.us/l/RolefvQNpr

User Image YouOnlyLiveTwice Posted - 3 months ago

$ANIK When they fire the incompetent CEO then you buy .. She has single-handedly destroyed this company

User Image jParkz Posted - 3 months ago

News out $ANIK (ANIK) Trading Report https://marketwirenews.com/news-releases/-anik-trading-report-5804276899019328.html $ANIK

User Image Aigner_Andreas Posted - 3 months ago

TD BUY $ANIK at 25.68, Supp 25.68 Resis 29.09 R13 HiLo 74% T1Y 36 buy 2.3 DIV N/A #Anika Ther #stocks #trading #finance #market

User Image epsguid Posted - 3 months ago

$ANIK reported $0.00, consensus was ($0.06) via @eWhispers #epsbeat http://eps.sh/d/anik

User Image DonCorleone77 Posted - 3 months ago

$ANIK Anika Therapeutics backs FY24 revenue view $168M-$173M, consensus $170.84M Sees FY24 adjusted EBITDA at lower end of $25M-$30M view.

User Image DonCorleone77 Posted - 3 months ago

$ANIK Anika Therapeutics reports Q2 adjusted EPS 17c, consensus 5c Reports Q2 revenue $41.9M, consensus $42.1M. "We are pleased with our financial performance in Q2 as we made meaningful progress on our re-focused business strategy and path to profitability," commented Cheryl R. Blanchard, Ph.D., Anika's President and CEO. "In July, as planned, we announced the full market release of our Integrity Implant System. This marks an important step in the continued expansion of our differentiated Regenerative Solutions portfolio. In the first half of 2024 during the limited market release, we completed more than double the number of cases than initially anticipated, demonstrating the significant surgeon pull for this transformational product. Integrity will be a true game changer for the future of rotator cuff and other tendon repairs. Our HA-based Regenerative Solutions portfolio, including Integrity, represents a key enabler for Anika's growth as we prepare for the US launch of Hyalofast by 2026 and file the first PMA module this year."

User Image Stock_Titan Posted - 3 months ago

$ANIK Anika Reports Second Quarter 2024 Financial Results https://www.stocktitan.net/news/ANIK/anika-reports-second-quarter-2024-financial-v0onf5ihvoux.html

User Image StockInvest_us Posted - 3 months ago

Signal alert: $ANIK - PivotPoint bottom https://stockinvest.us/l/9AGFSERnG3

User Image NVDAMillionaire Posted - 07/31/24

$ANIK Anika Therapeutics, Inc. (NASDAQ:ANIK): Delivering Meaningful Advancements in Early Intervention Orthopedic Care http://beyondspx.com/2024/07/30/anika-therapeutics-inc-nasdaqanik-delivering-meaningful-advancements-in-early-intervention-orthopedic-care/

User Image Stock_Titan Posted - 07/25/24

$ANIK Anika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024 https://www.stocktitan.net/news/ANIK/anika-to-issue-second-quarter-2024-financial-results-on-thursday-pasvf0llt33h.html

User Image DonCorleone77 Posted - 4 months ago

$ANIK Anika Therapeutics reports inducement grants under Nasdaq listing rule Anika Therapeutics announced that on July 1, 2024, Anika granted non-statutory stock options covering an aggregate of 2,500 shares of common stock at a per share exercise price of $25.85, which equaled the closing price of common stock on the Nasdaq Global Select Market on the grant date, to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, was approved by the compensation committee of the board of directors pursuant to a delegation of authority by the board of directors, and, in accordance with Nasdaq Listing Rule 5635(c)(4), was made as a material inducement to the grantee's acceptance of employment with Anika as a component of the grantee's employment compensation. Of the shares covered by the Options, one-third will vest on each of the first three anniversaries of the grant date, in each case for so long as the grantee provides continuous service to Anika through the relevant vesting date. Unless earlier terminated in accordance with their terms, the Options will expire on the tenth anniversary of the grant date and are otherwise subject to the terms and conditions of the equity award agreement approved by Anika. The Options were granted pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, which was not subject to stockholder approval.

User Image Doozio Posted - 4 months ago

$ANIK thru all $MNKD in 🧠⏰♾️

User Image Stock_Titan Posted - 4 months ago

$ANIK Anika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs https://www.stocktitan.net/news/ANIK/anika-announces-full-market-release-of-the-integrity-implant-system-gw4sny2kefgr.html

User Image Doozio Posted - 4 months ago

Jon $anik with his huckleberries soon once da 🧠 spreads thru ESPR n all MNKD TTWO in 🧠⏰♾️

User Image falconfly1 Posted - 4 months ago

$EYEN $ANIK and $KALA and $DERM and $BHC What is new and opportunity in $EYEN? 1 - Insider bought 1.5 million shares in July and paid 1 Million dollars 2 - Vanguard biggest institution in the world bought 5 million dollars for a call option 3 - First FDA MydCombi selling from April 2024, and they have a contract with Vision Source biggest Private Practice Optometrists in the USA and Canada. Vision Source multi a billion company. 4 - Second FDA's strongest eyedrop sales start the first of August and are expected to generate 15 to 40 million per quarter. 5 - 8 or 9 August earnings call, and it should be good. 6 - MicroPine and MicroLine are unmet need eyedrops for children and the result is coming in Q4 2024.

User Image TickerDD_com Posted - 4 months ago

From 6/24/2024, looking back across 21 Month-Ends for ANIK, Percentage Change of Average Monthly Price had More Positives (73%) while Percentage Change of Average Monthly Volume had All Positives (100%) $ANIK #ANIK #ANIKStock #TickerDD #ANIKPrice https://www.youtube.com/watch?v=HkAUdh6c3GI

User Image Doozio Posted - 5 months ago

Chop chop huckleberries Jon $anik. It’s 🧠⏰♾️

User Image StockInvest_us Posted - 05/29/24

Signal alert: $ANIK - Possible Runner https://stockinvest.us/l/i9F3RrTvDz

Analyst Ratings
Barrington Research Outperform Aug 9, 24
Stephens & Co. Equal-Weight May 29, 24
Barrington Research Outperform May 9, 24
Barrington Research Outperform Mar 14, 24
Stephens & Co. Equal-Weight Mar 14, 24
Barrington Research Outperform Jan 3, 24
Barrington Research Outperform Nov 3, 23
Barrington Research Outperform Aug 14, 23
Stephens & Co. Equal-Weight Aug 10, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Colleran David EVP, General Counsel.. EVP, General Counsel, Corp Sec May 11 Buy 21.37 1,500 32,055 9,867 05/12/22
Colleran David EVP, General Counsel.. EVP, General Counsel, Corp Sec Mar 14 Buy 26.652 1,500 39,978 8,367 03/16/22
Blanchard Cheryl R President, CEO, Dire.. President, CEO, Director Mar 11 Buy 25.59 8,100 207,279 59,992 03/14/22
Levitz Michael L EVP, CFO, Treasurer EVP, CFO, Treasurer Mar 11 Buy 24.619 4,000 98,476 15,924 03/14/22